Kamada Ltd. (KMDA)
$7.60-1.17%Close
SELLRECOVERY · day 87
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $438M
- Beta
- 0.14
- Div yield
- 5.53%
- P/E (TTM)
- 19.84
- Short % float
- 0.67%
- Days to cover
- 1.8
- SI change
- +30.3%
- 1W
- -3.68%
- 1M
- -6.06%
- vs SPY 1W
- -3.54%
- vs SPY 1M
- -8.56%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 48
- VALUE
- 26
- GROWTH
- 61
- GARP
- 87
- TYPE
- Dividend Compounder
Composite of Value · Growth · GARP
ROIC5.0%
REV YoY-
ROE8.4%
EPS YoY-
ROA5.8%
GROSS41
OP15
NET12
[VALUATION]
P/E TTM19.84
P/E FWD14.92
SECTOR PE20.48
INDUSTRY PE19.11
P/B1.63
P/FCF-
EV/EBITDA10.03
EV/EBIT-
PEG0.83
FCF YIELD-
RISK
INT COV-
D/E4.38
ALTMAN Z-
CURR RATIO4.06
ND/EBITDA-
BETA0.14
Company news
FAQ
- What is LOPJLB’s current signal on KMDA?
- LOPJLB’s latest quantitative signal on Kamada Ltd. (KMDA) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is KMDA in?
- Kamada Ltd. (KMDA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Kamada Ltd. (KMDA) do?
- Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant rec…